Form 4: Enanta CBO Sells Shares for Tax Obligations

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, sold 1,394 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Brendan Luu, Chief Business Officer of Enanta Pharmaceuticals Inc. (ENTA), reported a transaction on December 5, 2025.
• Luu sold 1,394 shares of Enanta common stock at a weighted-average price of $14.23 per share.
• The sale was a "sell to cover" transaction to satisfy tax withholding obligations arising from the settlement of a restricted stock unit (RSU) award granted on November 23, 2022.
• This transaction was non-discretionary and required by the terms of the RSU award.
• Following the sale, Luu beneficially owns 38,329 shares of Enanta common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary "sell to cover" to satisfy tax obligations related to an RSU award. It does not reflect a change in management's outlook on the company and is a common occurrence for executives receiving equity compensation.

Positives

• The transaction was non-discretionary, indicating it was not a voluntary sale based on a negative outlook.
• It was executed to fulfill tax obligations related to a compensation award, a routine event for executives.

Negatives

• A reduction in direct beneficial ownership by an executive, even if for tax purposes, slightly decreases their direct equity stake.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award.
• The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitor analysis.

Related Party Transactions

• The transaction relates to the settlement of a restricted stock unit award, which is a form of compensation between the company and an executive.

Stakeholder Impact

• Shareholders: Minimal impact, as it's a routine tax-related sale and not a discretionary divestment.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Brendan Luu, Chief Business Officer, Form 4, Insider transaction, Stock sale, Restricted Stock Unit, RSU, Tax withholding, Sell to cover